Literature DB >> 27252257

Multiparametric detection of autoantibodies in systemic lupus erythematosus.

P Budde1, H-D Zucht1, S Vordenbäumen2, H Goehler1, R Fischer-Betz2, M Gamer1, K Marquart1, P Rengers1, J Richter2, A Lueking1, P Schulz-Knappe1, M Schneider3.   

Abstract

Systemic lupus erythematosus (SLE) is a heterogeneous disease with respect to disease manifestations, disease progression and treatment response. Therefore, strategies to identify biomarkers that help distinguishing SLE subgroups are a major focus of biomarker research. We reasoned that a multiparametric autoantibody profiling approach combined with data mining tools could be applied to identify SLE patient clusters. We used a bead-based array containing 86 antigens including diverse nuclear and immune defense pathway proteins. Sixty-four autoantibodies were significantly (p < 0.05) increased in SLE (n = 69) compared to healthy controls (HC, n = 59). Using binary cut-off thresholds (95% quantile of HC), hierarchical clustering of SLE patients yields five clusters, which differ qualitatively and in their total number of autoantibodies. In two patient clusters the overall accumulated autoantibody reactivity of all antigens tested was 31% and 48%, respectively. We observed a positive association between the autoantibody signature present in these two patient clusters and the clinical manifestation of glomerulonephritis (GLMN). In addition, groups of autoantibodies directed against distinct intracellular compartments and/or biological motifs characterize the different SLE subgroups. Our findings highlight the relevant potential of multiparametric autoantibody detection and may contribute to a deeper understanding of the clinical and serological diversity of SLE.
© The Author(s) 2016.

Entities:  

Keywords:  Systemic lupus erythematosus; antigen; autoantibody signature; biomarker; cluster

Mesh:

Substances:

Year:  2016        PMID: 27252257     DOI: 10.1177/0961203316641770

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

Review 1.  Emerging technologies in autoantibody testing for rheumatic diseases.

Authors:  Nancy J Olsen; May Y Choi; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2017-07-24       Impact factor: 5.156

2.  A roadmap towards personalized immunology.

Authors:  Sylvie Delhalle; Sebastian F N Bode; Rudi Balling; Markus Ollert; Feng Q He
Journal:  NPJ Syst Biol Appl       Date:  2018-02-06

3.  Proteomic analysis to define predictors of treatment response to adalimumab or methotrexate in rheumatoid arthritis patients.

Authors:  Stephanie F Ling; Nisha Nair; Suzanne M M Verstappen; Anne Barton; Hans-Dieter Zucht; Petra Budde; Peter Schulz-Knappe; Darren Plant
Journal:  Pharmacogenomics J       Date:  2019-12-10       Impact factor: 3.550

4.  Profiling of IgG antibodies targeting unmodified and corresponding citrullinated autoantigens in a multicenter national cohort of early arthritis in Germany.

Authors:  Stefan Vordenbäumen; Ralph Brinks; Patrick Schriek; Angelika Lueking; Jutta G Richter; Petra Budde; Peter Schulz-Knappe; Hans-Dieter Zucht; Johanna Callhoff; Matthias Schneider
Journal:  Arthritis Res Ther       Date:  2020-07-06       Impact factor: 5.156

5.  Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection.

Authors:  Susan Cheng; Justyna Fert-Bober; Yunxian Liu; Joseph E Ebinger; Rowann Mostafa; Petra Budde; Jana Gajewski; Brian Walker; Sandy Joung; Min Wu; Manuel Bräutigam; Franziska Hesping; Elena Rupieper; Ann-Sophie Schubert; Hans-Dieter Zucht; Jonathan Braun; Gil Y Melmed; Kimia Sobhani; Moshe Arditi; Jennifer E Van Eyk
Journal:  J Transl Med       Date:  2021-12-30       Impact factor: 5.531

Review 6.  miRNA-Mediated Control of B Cell Responses in Immunity and SLE.

Authors:  Stephanie L Schell; Ziaur S M Rahman
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.